Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 10/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCND2 | P30279 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | MELK | Q14680 | 2/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27825351 | 0.91 | TBK1 (0.42) | TBK1PDPK1CDK4CCND1CCND2 | |
| SCHEMBL1285162 | 0.91 | CDK4 (0.41) | CDK4CCND1CCND2CCND3DAPK3 | |
| SCHEMBL1285233 | 0.88 | CDK4 (0.38) | TBK1PDPK1CDK4CCND1CCND2 | |
| SCHEMBL1285558 | 0.85 | CDK4 (0.45) | TBK1PDPK1CDK4CCND1CCND2 | |
| SCHEMBL1285070 | 0.84 | CDK4 (0.45) | TBK1PDPK1CDK4CCND1CCND2 | |
| SCHEMBL27844367 | 0.82 | CDK4 (0.41) | TBK1PDPK1CDK4CCND1CCND2 | |
| SCHEMBL1284677 | 0.77 | — | — | |
| SCHEMBL27825347 | 0.76 | CDK4 (0.46) | TBK1PDPK1CDK4CCND1CCND2 | |
| SCHEMBL15163200 | 0.75 | CDK4 (0.46) | TBK1PDPK1CDK4CCND1CCND2 | |
| SCHEMBL1284750 | 0.75 | MAP3K5 (0.46) | CDK4FLT3JAK3EGFRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | TBK1 17/4885PDPK1 280/4885CDK4 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.